
17609 (AP)

LISTING OF THE CLAIMS

1-13 (Cancelled)

14. (Currently amended) An ophthalmic solution comprising a therapeutically effective amount of a compound of formula I:



or a pharmaceutically acceptable salt thereof, in admixture with a non-toxic, ophthalmically acceptable liquid vehicle, packaged in a container suitable for metered application wherein the wavy segment represents an α or β bond, a dashed line represents the presence or absence of a bond, R^1 is H, R^2 is OH, R^3 is H;

W is O;

R is selected from the group consisting of CO_2R^4 , $CONR^4_2$, CH_2OR^4 , $CONR^4SO_2R^4$, and $P(O)(OR^4)$;

R4 is selected from the group consisting of H, phenyl and lower alkyl having from one to six carbon atoms;

Y is a covalent bond or is selected from the group consisting of CH_2 , O, S and N; and

Z is <u>benzothiophenyl</u> or <u>substituted benzothiophenyl</u> <u>heteroaryl a</u> <u>heterocyclic aromatic radical having from four to ten carbon atoms</u> and <u>including a heterocyclic atom selected from the group consisting of nitrogen</u>, oxygen and sulfur.

17609 (AP)

15. (Original) The ophthalmic solution of Claim 14 wherein said compound is a compound of Formula III

16-20 (Cancelled)

21. (Currently amended) A compound represented by formula I:

$$R^{1}$$
 R^{2}
 OR^{3}

wherein the wavy segment represents an α or β bond, a dashed line represents the presence or absence of a bond,

 R^1 is H, R^2 is OH, R^3 is H;

W is 0:

R is selected from the group consisting of CO_2R^4 , $CONR^4_2$, CH_2OR^4 . $CONR^4SO_2R^4$, and $P(O)(OR^4)$:

R4 is selected from the group consisting of H, phenyl and lower alkyl having from one to six carbon atoms;

Y is a covalent bond or is selected from the group consisting of CH2, O, S and N; and

17609 (AP)

Z is <u>benzothiophenyl</u> or <u>substituted</u> <u>benzothiophenyl</u> <u>heteroaryl</u> a <u>heterocyclic</u> aromatic radical having from four to ten carbon atoms and including a heterocyclic atom selected from the group consisting of nitrogen, oxygen and sulfur.

22. (Previously amended) The compound of claim 21 wherein said compound is represented by formula II:

wherein the hatched segment represents an α bond and the solid triangle represents a β bond.

23-34 (Cancelled)

35. The solution of claim 15, wherein said compound is selected from the group consisting of

(Z)-7-{(1R, 2R)-2-[(E)-5-(3-Chloro-benzo[b]thiophen-2-yl)-3-hydroxy-pent-1-enyl]-6-oxo-cyclohexyl}-hept-5-enoic acid;

(2)-7-{(1R,6R)-6-[(E)-5-(3-Chloro-benzo[b]thiophen-2-yl)-3-hydroxy-pent-1-enyl]-2-oxo-cyclohex-3-enyl}-hept-5-enoic acid;

Patent 17609 (AP)

- (Z)-7-{(1R,2R,3R)-2-[(E)-5-(3-Chloro-benzo[b]thiophen-2-yl)-3-hydroxy-pent-1-enyl]-3-hydroxy-6-oxo-cyclohexyl}-hept-5-enoic acid;
- 7-[(1R,2R,3R)-2-((E)-4-Benzo[b]thiophen-3-yl-3-hydroxy-but-1-enyl)-3-hydroxy-6-oxo-cyclohexyl]-hept-5-ynoic acid;
- (Z)-7-[(1R,2R,3R)-2-((E)-4-Benzo[b]thiophen-3-yl-3-hydroxy-but-1-enyl)-3-hydroxy-6-oxo-cyclohexyl]-hept-5-enoic acid; and
- (Z)-7-{(1R,2R,3R,6R)-6-Chloro-2-[(E)-5-(3-chloro-benzo[b]thiophen-2-yl)-3-hydroxy-pent-1-enyl]-3-hydroxy-cyclohexyl}-hept-5-enoic acid.
- 36. The compound 15 claim 22, selected from the group consisting of
- (Z)-7-{ $(1R,2R)-2-[(E)-5-(3-Chloro-benzo[b]thiophen-2-y1)-3-hydroxy-pent-1-enyl]-6-oxo-cyclohexyl}-hept-5-enoic acid;$
- (Z)-7-{(1R, 6R)-6-[(E)-5-(3-Chloro-benzo[b]thiophen-2-y1)-3-hydroxy-pent-1-enyl]-2-oxo-cyclohex-3-enyl}-hept-5-enoic acid;
- (Z)-7-{(1R,2R,3R)-2-[(E)-5-(3-Chloro-benzo[b]thiophen-2-yl)-3-hydroxy-pent-1-enyl]-3-hydroxy-6-oxo-cyclohexyl}-hept-5-enoic acid;
- 7-[(1R,2R,3R)-2-((E)-4-Benzo[b]thiophen-3-yl-3-hydroxy-but-1-enyl)-3-hydroxy-6-oxo-cyclohexyl]-hept-5-ynoic acid;
- (Z)-7-[(1R,2R,3R)-2-((E)-4-Benzo[b]thiophen-3-yl-3-hydroxy-but-1-enyl)-3-hydroxy-6-oxo-cyclohexyl]-hept-5-enoic acid; and

17609 (AP)

(Z)-7-{(1R,2R,3R,6R)-6-Chloro-2-[(E)-5-(3-chloro-benzo[b]thiophen-2-yl)-3-hydroxy-pent-1-enyl]-3-hydroxy-cyclohexyl}-hept-5-enoic acid.